In US market
Zydus Cadila announced that USFDA has given its final approval to market Mesalamine Delayed - Release Tablets USP, 1.2 g in the US market. Zydus Cadila was the first to file an Abbreviated New Drug Application for a generic version of Lialda (mesalamine). The product will be manufactured at the Maurya manufacturing facility.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content